Manila Times Business
Aplagon Appoints Carl Lindgren as Board Chair to Guide Later Stage Clinical and Corporate Development
Veteran life sciences executive brings over 30 years of strategic and commercial leadership as Aplagon advances through Phase 2 development in multiple thrombosis-inflammatory diseases HELSINKI, June 29, 2026 (GLOBE NEWSWIRE) -- Aplagon, a clinical-stage biotechnology company developing APAC, a first-in-class antiplatelet and anticoagulant therapeutic platform for thrombo-inflammatory diseases, today announced the appointment of Carl Lindgren as Chair of its Board of Directors. His experience sp
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Port Dickson, Kuala Terengganu and Cameron Highlands see rising family travel interest this school holiday, according to Agoda
1h ago
Leading Chinese Robotics Company Sets Sights on Off-Screen AI Education
1h ago
America split from monarchy 250 years ago. Trump's presidency is testing how far it's come
1h ago
Prepayments, Realkredit Danmark A/S
1h ago